Mahoney Michael F

Mahoney Michael F, Chairman, President & CEO, has demonstrated a clear selling bias across his recent insider transactions, with $43.2 million in total sales compared to $4.8 million in purchases across two companies—Boston Scientific (BSX) and CVS Health (CVS). His activity in BSX dominates the trading history, including a significant $14.9 million sale on February 2, 2026, followed by smaller dispositions totaling $1.2 million the same day. While he executed multiple purchases in BSX during February 2026—including a $9.9 million acquisition on February 13 and smaller buys ranging from $491,000 to $597,000—these were outweighed by the aggregate sell-side volume. His CVS transactions were less frequent, with a notable $2 million option exercise in February 2025 and restricted stock awards valued at $153,750 in November 2025. The pattern suggests Mahoney has been reducing his BSX exposure, with sales outpacing buys by nearly 9-to-1 in dollar terms. Recent activity shows a mix of acquisitions and dispositions, including three purchases between February 12–16, 2026, totaling approximately $1.7 million, but these follow much larger sales earlier in the month. The absence of any CVS trades since late 2025 indicates his focus remains on BSX. The transactions appear methodical, with no single trade drastically altering his position, though the February 2026 sales represent a meaningful reduction in holdings.